Day One Biopharmaceuticals (NASDAQ:DAWN) Insider Michael Vasconcelles Sells 2,728 Shares

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Michael Vasconcelles sold 2,728 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $31,644.80. Following the transaction, the insider directly owned 4,397 shares of the company’s stock, valued at $51,005.20. This represents a 38.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Day One Biopharmaceuticals Trading Down 2.7%

Shares of Day One Biopharmaceuticals stock opened at $11.56 on Thursday. The business has a 50-day moving average price of $10.34 and a two-hundred day moving average price of $8.57. Day One Biopharmaceuticals, Inc. has a 1-year low of $5.64 and a 1-year high of $13.20. The company has a market cap of $1.19 billion, a P/E ratio of -7.61 and a beta of -1.26.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several large investors have recently added to or reduced their stakes in DAWN. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Day One Biopharmaceuticals by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock worth $46,000 after purchasing an additional 1,029 shares during the last quarter. Federated Hermes Inc. bought a new position in Day One Biopharmaceuticals during the 3rd quarter valued at $39,000. Quarry LP bought a new position in Day One Biopharmaceuticals during the 3rd quarter valued at $49,000. Ameritas Investment Partners Inc. boosted its holdings in Day One Biopharmaceuticals by 44.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock worth $48,000 after acquiring an additional 2,264 shares during the last quarter. Finally, CWM LLC grew its stake in shares of Day One Biopharmaceuticals by 32.4% in the 4th quarter. CWM LLC now owns 8,373 shares of the company’s stock worth $78,000 after acquiring an additional 2,051 shares in the last quarter. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals News Roundup

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Wall Street support remains: several firms previously raised price targets or maintained buy/overweight views (Piper Sandler, JPMorgan, Needham, HC Wainwright), which provides longer‑term tailwinds for the name.
• Neutral Sentiment: Reported short interest data looks anomalous (effectively zero as of Feb. 17) and appears to contain reporting errors — this offers no clear directional signal and should be treated with caution. MarketBeat short interest note
• Negative Sentiment: Clustered insider selling by senior management on Feb. 17 likely pressured sentiment: CEO Jeremy Bender sold 15,459 shares, CFO Charles N. York II sold 6,065 shares and other insiders (Adam Dubow, Lauren Merendino, Michael Vasconcelles) sold additional stakes — roughly 36,500 shares in aggregate at about $11.60 each (~$423k). Such coordinated reductions by executives can be read negatively by the market. CEO Form 4 InsiderTrades summary
• Negative Sentiment: Zacks preview warns Day One may lack the setup for an earnings beat in the upcoming report, signaling the risk of a negative surprise that can further weigh on near‑term trading. Zacks preview

Wall Street Analyst Weigh In

Several brokerages recently issued reports on DAWN. Needham & Company LLC reissued a “buy” rating and set a $16.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, November 24th. TD Cowen initiated coverage on shares of Day One Biopharmaceuticals in a report on Tuesday, January 13th. They set a “buy” rating and a $34.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, November 24th. Zacks Research raised Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 26th. Finally, Piper Sandler upped their price target on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.